Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
OverviewMechanism of ActionHow To UseUsesBenfitsIndicationsMethod of AdministrationDosage StrengthsDosage FormsDietary RestrictionsContraindicationsWarnings and Precautions for usingAdverse ReactionsSide EffectsUse of Cefalotin in Specific PopulationsClinical Pharmacology Authored by Reviewed by References
Cefalotin

Cefalotin

Indications, Uses, Dosage, Drugs Interactions, Side effects
Cefalotin
Medicine Type :
Allopathy
Prescription Type:
Prescription Required
Approval :
DCGI (Drugs Controller General of India)
Schedule
Schedule H
Pharmacological Class:
First-generation cephalosporin antibiotics,
Therapy Class:
Antibiotic,

Cefalotin belongs to the pharmacological class of first-generation cephalosporin antibiotics.

Cefalotin is available as Injectable Powder For Injection and Intravenous Solution.

The common side effects involving the use of Cefalotin are nausea, vomiting, indigestion, intense abdominal pain, and diarrhea.

Cefalotin belongs to the pharmacological class of first-generation cephalosporin antibiotics.

Cefalotin is a cephalosporin antibiotic, a class of β-lactam antibiotics similar to penicillins, which binds to and inhibits penicillin-binding proteins (PBPs).

Cefalotin has been approved to relieve symptoms and also for the treatment and maintenance of surgical infection prophylaxis, staphylococcal infections, urinary tract infections, escherichia coli infections, klebsiella infections, proteus infections, respiratory tract infections, soft tissue infections, streptococcal infections.

Cefalotin is approved in the U.S., U.K., Germany, Japan, Malaysia, India, and China.

Cefalotin is available in the form of Injectable Powder For Injection and Intravenous Solution.

Cefalotin can be used in the following treatment:

  • Skin Diseases, Bacterial
  • Surgical infection prophylaxis
  • Staphylococcal Infections
  • Urinary Tract Infections
  • Escherichia coli Infections
  • Klebsiella Infections
  • Proteus Infections
  • Respiratory Tract Infections
  • Soft Tissue Infections
  • Streptococcal Infections

Cefalotin can help to relieve symptoms and also for the treatment and maintenance of surgical infection prophylaxis, staphylococcal infections, urinary tract infections, escherichia coli infections, klebsiella infections,proteus infections,respiratory tract infections,soft tissue infections,streptococcal infections.

Cefalotin is approved for use in the following clinical indications:

  • Skin Diseases, Bacterial
  • Surgical infection prophylaxis
  • Staphylococcal Infections
  • Urinary Tract Infections
  • Escherichia coli Infections
  • Klebsiella Infections
  • Proteus Infections
  • Respiratory Tract Infections
  • Soft Tissue Infections
  • Streptococcal Infections

Injectable Powder For Injection: Reconstituted into an injection, then administered by a registered medical practitioner

Intravenous Solution: Administered intravenously by a registered medical practitioner.

Intravenous

Prophylaxis for surgical infections

Adult: 2 grams as a slow injection of over 3-5 min or by an intermittent or continuous infusion thirty-sixty min prior to surgery, followed by a dose of 2 grams during surgery, then 2 grams 6 hourly after surgery for 24 hr which is continued for up to 72 hr for patients undergoing heart valve replacement or arthroplasty.

Parenteral

Susceptible infections

Adult: 0.5-1 g , four-six hourly by slow IV inj over three-five min or by intermittent or continuous infusion, deep IM injection. Max: 12 g daily.

Child: 80-160 mg/kg daily is divided doses, by deep Intramuscular injection, slow IV injection, or intermittent or continuous IV infusion.

Injection- 0.5g, 1g, 2g

Injectable Powder For Injection, Intravenous Solution

Avoid high acid foods like citrus fruits and juices like orange and grapefruit, soda and chocolates.

Alcohol intake might lead to nausea,vomiting and headache

Multivitamins and antacids contain minerals primarily magnesium calcium aluminum iron or zinc which binds to the antibiotic and refrain it from working. Spacing them at least for 2 hours after Cefalotin administration is recommended.

Cefalotin may be contraindicated under the following conditions:

  • Patients with known hypersensitivity to cephalosporins.
  • Previous immediate or severe hypersensitivity reaction to penicillin or to any other beta-lactam medicinal products.

The physician should closely monitor the patients and keep pharmacovigilance as follows:

Renal impairment:

The use of Cefalotin in patients with renal dysfunction should be monitored carefully. A modified dosage schedule in patients with a decreased renal function is essential.

Prolonged use:

As with all antibiotics, prolonged use might result in the overgrowth of non-susceptible organisms.

Hypersensitivity phenomena:

Hypersensitivity phenomena are found to more likely to occur in individuals who have previously demonstrated hypersensitivity and those with a history of hay fever, allergy, asthma, or urticaria. Special caution is required to determine any other type of previous hypersensitivity reactions to penicillin or to other beta-lactam medicinal products, as patients hypersensitive to these medicines might be hypersensitive to Cefalotin as well as (cross-allergy).

History of Colitis/Gastrointestinal disorders:

Cefalotin should be used cautiously in those patients with a known history of gastrointestinal/collitis disorders.

Pediatric use: As these products might contain arginine, they should be used cautiously in the pediatric population.

Alcohol Warning

Usage of alcohol should be avoided while on Cefalotin medication, as alcohol can worsen the effects of any underlying disease condition, including conditions such as dizziness, blurred vision, etc.

Pregnancy Warning

Category B:

There are no well-done studies that have been done on humans with Cefalotin. But in animal studies, pregnant animals were given this medication, and the babies did not show any medical issues related to this medication.

Food Warning

No sufficient scientific evidence is traceable regarding the use and safety of Cefalotin in concurrent use with any particular food.

The adverse reactions related to Cefalotin can be categorized as follows:

  • Acute renal tubular necrosis
  • Acute interstitial nephritis
  • Hypersensitivity reactions such as skin rashes, urticaria, eosinophilia, fever, serum sickness-like reactions
  • Neutropenia
  • Thrombocytopenia
  • Bleeding complications related to hypoprothrombinemia and/or platelet dysfunction
  • Nephrotoxicity
  • Thrombophlebitis (IV) and pain (IM) at the injection site
  • Rarely, hemolytic anemia
  • Transient increase in liver enzyme values
  • Convulsions and other signs of CNS toxicity
  • Agranulocytosis
  • Hepatitis
  • Cholestatic jaundice
  • GI effects (e.g., nausea, vomiting, diarrhea)
  • Potentially Fatal: pseudomembranous colitis, Anaphylaxis

The clinically relevant drug interactions ofCefalotin is briefly summarized here:

Increased risk of nephrotoxicity with aminoglycosides such as gentamicin, tobramycin, and loop diuretics such as furosemide. Antagonistic effect with bacteriostatic antibacterials. Probenecid might inhibit the renal excretion of cefalotin.

The following are the side effects involving Cefalotin:

● Indigestion

● Nausea

● Diarrhea

● Vomiting

● Intense Abdominal Pain

Pregnancy

Category B:

There are no well-done studies that have been done on humans with Cefalotin. But in animal studies, pregnant animals were given this medication, and the babies did not show any medical issues related to this medication.

Pharmacodynamics

Cefalotin or cephalothin is a semisynthetic first-generation cephalosporin having a broad spectrum of antibiotic activity that is found to be administered parenterally.

Pharmacokinetics

  • Absorption: Cefalotin is found to be poorly absorbed from the GI tract. Time to peak plasma concentration: W/in 30 min (IM); 15 min (IV).
  • Distribution: Cefalotin is found to be widely distributed into the body tissues and fluids except for the brain and Cerebrospinal fluid (low and unpredictable concentrations). Cefalotin is found to cross the placenta and enters breast milk (low concentrations). Plasma protein binding: Approx 70%.
  • Metabolism: Hepatic via deacetylation.
  • Excretion: Via urine (approx 60-70%) and bile (very small amount). Plasma half-life: Approx 30-50 min.
  1. https://www.samhealth.org/about-samaritan/news-search/2022/10/07/antibiotics-foods-to-eat-and-foods-to-avoid#:~:text=Bland foods – In general, foods,help with diarrhea from antibiotics.
  2. https://www.webmd.com/drugs/2/drug-19324/cephalothin-injection/details/list-sideeffects
  3. https://www.mims.com/philippines/drug/info/cefalotin?mtype=generic
  4. https://www.drugs.com/sfx/cephalothin-side-effects.html#:~:text=Manifestations may include urticarial or,rash are often also present.
  5. https://www.rxwiki.com/cefalotin
  6. https://www.drugfuture.com/chemdata/Cephalothin.html
  7. https://www.ndrugs.com/?s=cefalotin&t=overdose
  8. https://www.tabletwise.net/medicine/cefalotin-sodium/amp
  9. https://go.drugbank.com/drugs/DB00456
  10. https://pubchem.ncbi.nlm.nih.gov/compound/Cephalothin
  11. https://www.healthdirect.gov.au/medicines/brand/amt,3041011000036109/cephalothin-dbl
undefined
Sonali R Muralidhar
I am Sonali R Muralidhar currently residing at Madurai.I have completed my Master’s in Pharmacy with my core subject as Pharmaceutics. I am interested in Pharmaceutical research , medical content writing, Biopharmaceutics , regulatory affairs , novel drug delivery, targeted drug delivery.
undefined
Dr JUHI SINGLA
Dr JUHI SINGLA has completed her MBBS from Era’s Lucknow Medical college and done MD pharmacology from SGT UNIVERSITY Gurgaon. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Published on: 4 March 2023 5:59 PM GMT
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok